Evidence map›Paper›PMID 25368699›Full record

ArticleJournal of clinical medicine research2015

Clinical markers of Crohn's disease severity and their association with opiate use.

Mary Cheung, Sundas Khan, Meredith Akerman, Chun Kit Hung, Kaitlyn Vennard, Nicholas Hristis, Keith Sultan

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical medicine research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mary CheungDepartment of Medicine, Division of Gastroenterology, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY 11030, USA.
Sundas KhanDepartment of Medicine, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY 11030, USA.
Meredith AkermanThe Feinstein Institute for Medical Research, Manhasset, NY 11030, USA.
Chun Kit HungDepartment of Medicine, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY 11030, USA.
Kaitlyn VennardDepartment of Medicine, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY 11030, USA.
Nicholas HristisDepartment of Medicine, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY 11030, USA.
Keith SultanDepartment of Medicine, Division of Gastroenterology, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY 11030, USA.
Hofstra University · USFeinstein Institute for Medical Research · USIJ Research (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe safety of opiate use for patients with Crohn's disease (CD) has long been a concern. The recent Crohn's therapy, resource, evaluation, and assessment tool (TREAT) registry update has added to these concerns by demonstrating an association of opiate use with an increased risk of infection and death in CD. While the association is clear, the relationship of opiates to these negative outcomes is not. It is unknown whether opiates are a contributing factor to these negative outcomes or if their use is merely a marker of more severe disease. We hypothesized that opiate use is not harmful in CD but is a marker of disease severity and would be associated with commonly accepted clinical markers of severe CD such as early age at CD onset, disease duration, small intestinal involvement, a history of fistula or stricture, and lower quality of life (QOL) scores.

methodsData on CD history including pain medication usage were obtained from an interviewer directed survey of patients admitted to two tertiary care hospitals over a 2-year period. CD as the primary admitting diagnosis was not required. Active opiate use was defined by usage within the past month prior to admission.

resultsA total of 133 patients were approached to participate, of whom 108 consented to the survey, and 51 were active opiate users. Opiate using CD patients were more commonly smokers (22% vs. 3.45%, P < 0.010), had fistulas (40% vs. 22.4%, P < 0.048) and had a poorer quality of life score by short form inflammatory bowel disease questionnaire (mean 3.80 vs. 4.34, P < 0.036) than non-opiate users. No difference was found between opiate users and non-users for age of diagnosis, disease duration, or a history of strictures.

conclusionsThe study findings demonstrate that opiate use in CD is associated with markers of disease severity including fistulas, smoking, and lower QOL scores. The findings suggest that opiates may not be directly harmful to patients with CD, but may merely be another marker of disease severity. However, given opiates unproven benefits for long term CD pain control and risk of dependence, caution should still be exercised in their use.

Indexed as

Crohn’s diseaseFistulasInflammatory bowel diseaseOpiatesSmoking

Identifiers

PMID25368699
PMCPMC4217751
OpenAlexW2167256039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.